New PET tracer aims to spot hidden cancers with precision
NCT ID NCT07172503
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study tests a new radioactive imaging agent called 68Ga-NOTA-GPA33 nanobody, which targets a protein (GPA33) found on some cancer cells. Researchers will use PET scans to see if this agent can better detect and stage colorectal, stomach, and pancreatic cancers in 56 patients and healthy volunteers. The goal is to improve diagnosis and staging compared to standard methods.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
68Ga-NOTA-GPA33 nanobody (a radioactive imaging agent)
What this could lead to
If successful, this could provide a more accurate way to detect and stage certain cancers using PET scans, potentially improving treatment decisions.
What could go wrong
This is an early diagnostic study with only 56 participants, so results may not apply to all patients. The imaging agent's accuracy and safety are still being evaluated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••